Blurbs

Analysts’ Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), scPharmaceuticals (SCPH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZResearch Report), scPharmaceuticals (SCPHResearch Report) and Processa Pharmaceuticals (PCSAResearch Report) with bullish sentiments.

Jazz Pharmaceuticals (JAZZ)

Jefferies analyst Akash Tewari maintained a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $185.00. The company’s shares closed last Wednesday at $140.00.

According to TipRanks.com, Tewari is a 5-star analyst with an average return of 18.5% and a 43.7% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Third Harmonic Bio, Inc., and Arvinas Holding Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $196.75 average price target, which is a 38.8% upside from current levels. In a report issued on October 26, RBC Capital also maintained a Buy rating on the stock with a $206.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

scPharmaceuticals (SCPH)

In a report released yesterday, Glen Santangelo from Jefferies reiterated a Buy rating on scPharmaceuticals, with a price target of $14.00. The company’s shares closed last Wednesday at $5.38.

According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 9.1% and a 57.5% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Phathom Pharmaceuticals, and Bausch Health Companies.

Currently, the analyst consensus on scPharmaceuticals is a Strong Buy with an average price target of $14.25, implying a 152.2% upside from current levels. In a report issued on October 28, SVB Securities also maintained a Buy rating on the stock with a $11.00 price target.

Processa Pharmaceuticals (PCSA)

Maxim Group analyst Naz Rahman maintained a Buy rating on Processa Pharmaceuticals yesterday and set a price target of $9.00. The company’s shares closed last Wednesday at $2.04, close to its 52-week low of $1.50.

According to TipRanks.com, Rahman is ranked 0 out of 5 stars with an average return of -38.3% and a 16.9% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Virpax Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Processa Pharmaceuticals with a $8.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on JAZZ:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More